Table 4.

Mean changes in log-neurofilament light in plasma (pNfL) values between baseline and on-treatment measures using unadjusted and adjusted analysis.

	Changes in log-pNfL values without adjustment analysis; exp(β) (95% CI)	p value	Changes in log-pNfL values with adjustment variables; exp(β) (95% CI)	p value
PRE	Ref		Ref
RTX	0.74 (0.60–0.91)	0.008	0.79 (0.68–0.93)	0.005
TCZ	0.65 (0.53–0.79)	<0.001	0.65 (0.56–0.75)	<0.001

All estimates were calculated with a mixed effect model for repeated measurements with three different treatment group as the main explanatory variable, adjusted with or without baseline clinical variable: age, EDSS score, recent relapse(yes/no), prior treatment, and baseline pNfL levels; The estimates have been back transformed to the original scale. CI, confidence interval; EDSS, Expanded Disability Status Scale; pNfL, plasma neurofilament light chain; PRE, prednisone; Ref, reference; RTX, Rituximab; TCZ, tocilizumab.